Uncategorized

Stocks to Lookout for: PetIQ, Inc. (NASDAQ:PETQ) & Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)

PetIQ, Inc. (NASDAQ:PETQ)

PetIQ, Inc. is a pet medication and wellness company. Its product consists of Rx Medications, OTC Medications and Supplies, Health and Wellness Products. The Company serves retail stores across the mass, club, grocery, pharmacy and e-commerce channels. PetIQ, Inc. is based in Eagle, United States.

PetIQ, Inc. (NASDAQ:PETQ)’s Financial Overview

PetIQ, Inc. (NASDAQ) surged 0.83% yesterday to close its trading session at $29.02. The company has 1 year Price Target of $42.75. PetIQ, Inc. has 52-Week high of $43.93 and 52-Week Low of $17.56. The stock touched its 52-Week High on 43.93 and 52-Week Low on 17.56. The stock traded with the volume of 166914 shares yesterday. The firm shows the market capitalization of $821.56 Million.

PetIQ, Inc. (NASDAQ) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $0.32/share against the analyst consensus estimate of $0.26/share. The difference between the actual and expected EPS is $0.06 a share with a surprise factor of 23.1%.

The firm is trading with SMA20 of 1.74 Percent, SMA50 of 5.34 Percent and SMA200 of 0.44 percent. PetIQ, Inc. has P/S value of 1.75 while its P/B value stands at 2.62. Similarly, the company has Return on Assets of -0.2 percent, Return on Equity of -0.4 percent and Return on Investment of 15.3 Percent. The company shows Gross Margin and Operating Margin of 16.4 percent and 2.7 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 1.4 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 4 analysts offering 12-month price forecasts for PetIQ Inc have a median target of 41.00, with a high estimate of 50.00 and a low estimate of 39.00. The median estimate represents a +41.28% increase from the last price of 29.02.

PetIQ, Inc. is estimated to report earnings on 03/12/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.07. The reported EPS for the same quarter last year was $0.19.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company’s lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)’s Financial Outlook

The 6 analysts offering 12-month price forecasts for Bellicum Pharmaceuticals Inc have a median target of 17.50, with a high estimate of 23.00 and a low estimate of 14.00. The median estimate represents a +431.91% increase from the last price of 3.29.

Bellicum Pharmaceuticals, Inc. is estimated to report earnings on 03/12/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.59. The reported EPS for the same quarter last year was $-0.61.

According to Zacks Investment Research, Bellicum Pharmaceuticals, Inc. has a Consensus Recommendation of 1.2. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock surged 0.92% and closed its last trading session at $3.29. The company has the market capitalization of $147.49 Million. The stock has 52-week high of $10.26 and 52-Week low of $2.74. The firm touched its 52-Week high on 10.26 and 52-Week low on 2.74. The company has volume of 164205 shares. The company has a total of 44.83 Million shares outstanding.

Bellicum Pharmaceuticals, Inc. (NASDAQ) in the last quarter reported its actual EPS of $-0.55/share where the analyst estimated EPS was $-0.58/share. The difference between the actual and Estimated EPS is $0.03. This shows a surprise factor of 5.2 percent.

The company has YTD performance of 12.67 percent. Beta for Bellicum Pharmaceuticals, Inc. stands at 1.55 while its ATR (average true range) is 0.19. The company has Weekly Volatility of 4.37%% and Monthly Volatility of 5.84%%.

Bellicum Pharmaceuticals, Inc. has distance from 20-day Simple Moving Average (SMA20) of -0.48%, Distance from 50-Day Simple Moving Average of -6 percent and Distance from 200-Day Simple Moving Average of -43.65%.

The Company currently has ROA (Return on Assets) of 0 percent, Return on Equity (ROE) of 0 Percent and Return on Investment (ROI) of -74.5% with Gross margin of 54.8 percent and Operating & Profit margin of 0% and 0% respectively.